- Report
- February 2022
- 40 Pages
Japan
From €1438EUR$1,500USD£1,202GBP
- Report
- February 2022
- 40 Pages
Russia
From €1438EUR$1,500USD£1,202GBP
- Report
- February 2022
- 40 Pages
South Korea
From €1438EUR$1,500USD£1,202GBP
- Report
- February 2022
- 40 Pages
United States
From €1438EUR$1,500USD£1,202GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €1438EUR$1,500USD£1,202GBP
- Report
- November 2022
- 335 Pages
Global
From €3422EUR$3,570USD£2,860GBP
The Endothelin Receptor Antagonist (ERA) market is a subset of the cardiovascular drug market. ERA drugs are used to treat a variety of cardiovascular conditions, including hypertension, pulmonary arterial hypertension, and congestive heart failure. These drugs work by blocking the action of endothelin, a hormone that can cause constriction of the blood vessels. This helps to reduce blood pressure and improve blood flow. ERA drugs are generally well-tolerated and have few side effects.
The ERA market is highly competitive, with several major pharmaceutical companies offering products. These include Amgen, Bayer, Merck, Novartis, and Pfizer. Other companies, such as Actelion, Gilead, and United Therapeutics, also offer ERA drugs. These companies are continually researching and developing new drugs to improve the treatment of cardiovascular conditions. Show Less Read more